ArticleEuropean journal of neurology2018
Assessment of bulbar function in amyotrophic lateral sclerosis: validation of a self-report scale (Center for Neurologic Study Bulbar Function Scale).
Article in European journal of neurology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 46 citations in OpenAlex.
- A systematic review of non-motor symptom evaluation in clinical trials for amyotrophic lateral sclerosis.Journal of neurology · 2022Pooled it
- Multiplex Panel Detects Glial and Inflammatory Biomarker Signatures in Sporadic and C9orf72-ALS.Neurology(R) neuroimmunology & neuroinflammation · 2026Article
- Delivering effective non-invasive ventilation in amyotrophic lateral sclerosis using intensive remote support (DENIM): protocol for an embedded process evaluation in a hybrid type 3 implementation-effectiveness trial.Implementation science communications · 2026Article
- Review
- To Treat or Not to Treat: A Scoping Review of Speech Treatment for Dysarthria in Amyotrophic Lateral Sclerosis (ALS).Healthcare (Basel, Switzerland) · 2025Review
- Comparison of Demographics: National Amyotrophic Lateral Sclerosis Registry and Clinical Trials Data.Journal of racial and ethnic health disparities · 2025Article
- Construct Validity of the Amyotrophic Lateral Sclerosis Bulbar Dysfunction Index-Remote.American journal of speech-language pathology · 2025Article
- Validation of the Center for Neurologic Study Bulbar Function Scale-Chinese version in a population with amyotrophic lateral sclerosis.Orphanet journal of rare diseases · 2024Article
- Observational
- Multimodal layer modelling reveals in vivo pathology in amyotrophic lateral sclerosis.Brain : a journal of neurology · 2024Article
- Development of a Rasch-Built Amyotrophic Lateral Sclerosis Impairment Multidomain Scale to Measure Disease Progression in ALS.Neurology · 2023Article
- The Current State and Future Directions of Swallowing Care in Amyotrophic Lateral Sclerosis.Current physical medicine and rehabilitation reports · 2023Article
- Bulbar involvement and cognitive features in amyotrophic lateral sclerosis: a retrospective study on 347 patients.Frontiers in aging neuroscience · 2023Article
- A machine-learning based objective measure for ALS disease severity.NPJ digital medicine · 2022Article
- Article
- Qualitative measures that assess functional disability and quality of life in ALS.Health and quality of life outcomes · 2022Review
- An Automated Tongue Tracker for Quantifying Bulbar Function in ALS.Frontiers in neurology · 2022Article
- Validation of Articulatory Rate and Imprecision Judgments in Speech of Individuals With Amyotrophic Lateral Sclerosis.American journal of speech-language pathology · 2021Article
- Patient reported outcome measures (PROMs) in amyotrophic lateral sclerosis.Journal of neurology · 2020Article
- Early detection and tracking of bulbar changes in ALS via frequent and remote speech analysis.NPJ digital medicine · 2020Article
Corrections and comments
- Erratum issuedErratum.2018
Authors and funding
9 authors at 6 institutions in 1 country.
Funding
Abstract
background and purposeImpaired bulbar functions of speech and swallowing are among the most serious consequences of amyotrophic lateral sclerosis (ALS). Despite this, clinical trials in ALS have rarely emphasized bulbar function as an endpoint. The rater-administered Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) or various quality-of-life measures are commonly used to measure symptomatic benefit. Accordingly, we sought to evaluate the utility of measures specific to bulbar function in ALS.
methodsWe assessed bulbar functions in 120 patients with ALS, with clinicians first making direct observations of the degree of speech, swallowing and salivation impairment in these subjects. Clinical diagnosis of bulbar impairment was then compared with ALSFRS-R scores, speech rate, time to swallow liquids and solids, and scores obtained when patients completed visual analog scales (VASs) and the newly-developed 21-question self-administered Center for Neurologic Study Bulbar Function Scale (CNS-BFS).
resultsThe CNS-BFS, ALSFRS-R, VAS and timed speech and swallowing were all concordant with clinician diagnosis. The self-report CNS-BFS and ALSFRS-R bulbar subscale best predicted clinician diagnosis with misclassification rates of 8% and 14% at the optimal cut-offs, respectively. In addition, the CNS-BFS speech and swallowing subscales outperformed both the bulbar component of the ALSFRS-R and speech and swallowing VASs when correlations were made between these scales and objective measures of timed reading and swallowing.
conclusionsBased on these findings and its relative ease of administration, we conclude that the CNS-BFS is a useful metric for assessing bulbar function in patients with ALS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.